WEGO威高

山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

ANNOUNCEMENT MADE IN ACCORDANCE WITH RULES 13.17 AND 13.18 OF THE LISTING RULES

FIVE YEARS LONG-TERM LOAN FACILITY

This announcement is made in accordance with the requirement under Rules 13.17 and 13.18 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited ("**Listing Rules**"). The board of directors (the "**Board**") of Shandong Weigao Group Medical Polymer Company Limited (the "**Company**" or the "**Borrower**") is pleased to announce that, on 27 January 2015, the Company entered into a five (5) years loan agreement (the "**Loan Agreement**") for the principal amount of RMB600 million (approximately HK$744 million) (the "**Loan**") with the International Finance Corporation ("**IFC**"), a member of the World Bank Group and the largest global development institution focused exclusively on the private sector. The Company shall repay the Loan in one lump sum on 15 March 2020.

The Board considers that the Loan will facilitate the business development of Weigao Blood Purification Products Company Limited ("**Weigao Blood**") to establish blood dialyzer and related products manufacturing capacity and to open additional hemodialysis centers in China. Weigao Blood is 70% held by the Company.

Under the Loan Agreement, the Borrower has agreed, among other terms and conditions that an event of default will arise if any of the following events, among others occurs:

1. a failure by Weigao Holding Company Limited (the "**Weigao Holding**") at any time and for any reason to own at least thirty-five per cent (35%) interests in the Borrower's share capital;

* *For identification purpose only*

2. the Board shall cease to consist of half of continuing executive directors;

3. Mr. Huawei Zhang, shall cease to be an executive director of the Borrower;

4. the Borrower fails to comply with any of its obligations under the Loan Agreement and any such failure continues for a period of thirty (30) days after the date on which that failure occurs;

5. any representation or warranty made in the Loan Agreement is found to be incorrect in any material respect; and

6. any of the Borrower's shares cease to be listed on the Stock Exchange of Hong Kong Limited.

Under the share pledge agreement entered into between Weigao Holding, the Company and IFC on 27 January 2015 (the "**Share Pledge Agreement**"), Weigao Holding must ensure at any time the equivalent market value of the shares pledged shall be equivalent to at least one point five (1.5) times the outstanding amount of the loan. The initial shares pledged under the Share Pledge Agreement is 230 million non listed domestic shares held by Weigao Holding. As at the date of this announcement, Weigao Holding holds 2,159,755,676 shares in the Company, representing 48.25% of the total issued share capital of the Company.

By order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

Weihai, Shandong, the PRC, 27 January 2015

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei *(Executive Director)*
Mr. Wang Yi *(Executive Director)*
Mr. Gong Jian Bo *(Executive Director)*
Mr. Xia Lie Bo *(Executive Director)*
Mr. Chen Xue Li *(Non-executive Director)*
Mrs. Zhou Shu Hua *(Non-executive Director)*
Mr. Lo Wai Hung *(Independent non-executive Director)*
Mr. Li Jia Miao *(Independent non-executive Director)*
Mrs. Fu Ming Zhong *(Independent non-executive Director)*
Mrs. Wang Jin Xia *(Independent non-executive Director)*